share_log

Investors in Encompass Health (NYSE:EHC) Have Seen Solid Returns of 104% Over the Past Five Years

Investors in Encompass Health (NYSE:EHC) Have Seen Solid Returns of 104% Over the Past Five Years

在過去的五年裏,投資Encompass Health (紐交所:EHC)的投資者獲得了104%的穩健回報。
Simply Wall St ·  08/22 06:07

The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunately for shareholders, while the Encompass Health Corporation (NYSE:EHC) share price is up 52% in the last five years, that's less than the market return. Some buyers are laughing, though, with an increase of 28% in the last year.

長期投資的主要目的是賺錢。此外,您通常希望股價的增長速度超過市場。不幸的是對股東而言,儘管Encompass Health Corporation (紐交所:EHC) 的股價在過去五年中上漲了52%,但這低於市場的回報。不過,有些買家則在過去一年裏獲得了28%的增長。

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

那麼,讓我們調查一下並查看公司的長期表現是否符合基本業務的進展。

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

禾倫·巴菲特在他的文章《格雷厄姆與多德維爾的超級投資者》中描述了股票價格並不總是合理地反映了一家企業的價值。考慮市場對一家公司的看法如何轉變的一種不完美但簡單的方法,是將每股收益(EPS)的變化與股價的動態進行比較。

Over half a decade, Encompass Health managed to grow its earnings per share at 5.3% a year. This EPS growth is lower than the 9% average annual increase in the share price. So it's fair to assume the market has a higher opinion of the business than it did five years ago. That's not necessarily surprising considering the five-year track record of earnings growth.

在過去的五年中,Encompass Health成功以每年5.3%的速度增長其每股收益。這種每股收益增長低於股價平均年增長率的9%。因此,可以合理地認爲市場對該業務的看法比五年前更高。考慮到五年來收益增長的記錄,這並不令人意外。

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

下面可以看到每股收益隨時間的變化情況(通過點擊圖像來查看確切數值)。

1724321224867
NYSE:EHC Earnings Per Share Growth August 22nd 2024
紐交所:EHC每股收益增長2024年8月22日

We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. This free interactive report on Encompass Health's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

我們喜歡看到內部人在過去十二個月中購買股票。即便如此,未來的盈利將對當前股東是否賺錢更爲重要。如果你想進一步調查該股票,那麼Encompass Health的盈利、營收和現金流的這份免費交互式報告是一個絕佳的起點。

What About Dividends?

那麼分紅怎麼樣呢?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of Encompass Health, it has a TSR of 104% for the last 5 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!

在考慮投資回報時,重要的是考慮總股東回報(TSR)和股價回報之間的差異。TSR是一個回報計算,它考慮了現金股息的價值(假設任何股息收入都是再投資的)以及任何折價的資本增發和剝離交易的計算值。可以說TSR給出了更全面的股票回報情況。就Encompass Health而言,過去5年的TSR爲104%。這超過了我們之前提到的股價回報。這主要是其分紅支付的結果!

A Different Perspective

不同的觀點

Encompass Health shareholders have received returns of 29% over twelve months (even including dividends), which isn't far from the general market return. Most would be happy with a gain, and it helps that the year's return is actually better than the average return over five years, which was 15%. Even if the share price growth slows down from here, there's a good chance that this is business worth watching in the long term. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for Encompass Health you should be aware of.

Encompass Health股東在過去12個月內獲得了29%的回報(甚至包括股息),這與整體市場回報相差不遠。大多數人對於獲得盈利會感到高興,並且令人欣慰的是,今年的回報實際上比過去5年的平均回報(15%)更好。即使股價增長從此變緩,對於長期來說,這是一個值得關注的企業。我發現長期來看股價作爲業績的代理非常有趣。但是爲了真正獲得洞察力,我們還需要考慮其他信息。就此而言:我們已經發現了Encompass Health的2個警示信號,你應該注意。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar).

如果您喜歡與管理層共同購買股票,那麼您可能會喜歡這個免費的公司列表(提示:大多數公司沒有受到關注)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論